GlaxoSmithKline
(GSK) and Biological E Limited (Biological E.), a leading Indian vaccines
company, today announced an agreement to form a 50/50 joint venture (JV) for the
early stage research and development of a six-in-one combination paediatric
vaccine to help protect children in India and other developing countries from
polio and other infectious diseases.
If approved, the
vaccine, which would combine GSK’s injectable polio vaccine (IPV) and Biological
E’s pentavalent vaccine for diphtheria, tetanus, whooping cough (whole cell
pertussis), hepatitis B, and Haemophilus influenzae type b, could be the first
of its kind. The vaccine would enable fewer injections for children thereby
improving compliance in immunisation schedules. The fully liquid formulation of
the vaccine also means it would be ready to use with no additional ingredients
or materials required, freeing up space at local storage facilities.
The JV will
bear the development costs for the candidate vaccine, which is expected to enter
phase 1 development in the next two years. A small initial cash investment will
be made by both companies to cover start-up costs for the JV and subsequent
development costs will be split equally
GlaxoSmithKline – one of the world’s leading
research-based pharmaceutical and healthcare companies – is committed to
improving the quality of human life by enabling people to do more, feel better
and live longer. For further information please visit www.gsk.com
Biological
E is
a privately held company established in 1953. Biological E. Limited (Bio E) is a
globally focused biopharmaceutical company that develops, manufactures and
markets innovative vaccines and biologics that respond to health care needs
worldwide. The company’s product development efforts are driven by an
internationally experienced management team and the company has several
strategic partnerships with leading biotechnology and pharmaceutical companies
and research institutes around the world.
No comments:
Post a Comment
Please share your views to enrich the discussion